Pfizer ceases Phase III trial of lung cancer drug

12/30/2009 | Yahoo!

Pfizer has decided to stop the Phase III trial of figitumumab, its drug candidate for lung cancer, after an analysis found that combining the drug with paclitaxel and carboplatin would be unlikely to satisfy the study's primary endpoint. "While these findings are disappointing, Pfizer is committed to using information gained from this study to refine the design of future trials of figitumumab in non-small cell lung cancer," a Pfizer executive said.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Director of Governmental Programs
Bluegrass Family Health
Lexington, KY